SEC Comment Letter for Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Sep 28, 2017
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: Sept. 28, 2017 · CIK: 0001649989 · Accession: 0000000000-17-034588
AI Filing Summary & Sentiment
Letter
September 28, 2017 Lawrence A. Kenyon Chief Financial Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, New Jersey 08512 Oncobiologics, Inc. Revised Preliminary Proxy Statement on Schedule 14A Filed September 27, 2017 File No. 001-37759Re: Dear Mr. Kenyon: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
September 28, 2017 Lawrence A. Kenyon Chief Financial Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, New Jersey 08512 Oncobiologics, Inc. Revised Preliminary Proxy Statement on Schedule 14A Filed September 27, 2017 File No. 001-37759Re: Dear Mr. Kenyon: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance